Zhihong Yun
Toronto, ON M5G1L7, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Triple-modality therapy maximizes antitumor immune responses in a mouse model of mesothelioma.
Journal: Science translational medicine
Published: July 24, 2020
Foxp3+ Regulatory T Cell Depletion after Nonablative Oligofractionated Irradiation Boosts the Abscopal Effects in Murine Malignant Mesothelioma.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: April 30, 2020
Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma.
Journal: BMC cancer
Published: November 15, 2017
Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 01, 2016
Activation of CD1d-restricted natural killer T cells can inhibit cancer cell proliferation during chemotherapy by promoting the immune responses in murine mesothelioma.
Journal: Cancer immunology, immunotherapy : CII
Published: December 04, 2013
Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: September 03, 2013
CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma.
Journal: Molecular cancer therapeutics
Published: May 16, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026